Lipocine Inc. — Q2 2023 Form 10-Q
Business context and period. Lipocine is a clinical-stage biopharmaceutical company developing oral drug-delivery products, including candidates for postpartum depression, epilepsy and liver disease. This unaudited report covers the three and six months ended June 30, 2023; comparisons are to the same 2022 periods.
Financial performance and liquidity
| Metric | Q2 2023 | Q2 2022 | Six months 2023 | Six months 2022 |
|---|---|---|---|---|
| Revenue | $0 | $500,000 | $54,990 | $500,000 |
| Research and development | $2.52 million | $2.90 million | $5.62 million | $4.79 million |
| General and administrative | $1.44 million | $1.13 million | $2.73 million | $2.37 million |
| Operating loss | $3.96 million | $3.53 million | $8.29 million | $6.66 million |
| Net loss | $3.55 million | $2.63 million | $7.42 million | $6.12 million |
| Loss per share, basic | $0.68 | $0.50 | $1.42 | $1.17 |
- Revenue remains immaterial and primarily reflects licensing arrangements, not product sales. Q2 2022 revenue was a non-refundable Antares fee for extending its LPCN 1111 option; 2023 year-to-date revenue came from related-party Spriaso.
- Operating margins are not meaningful given the absence of material revenue. Higher six-month R&D spending principally reflected LPCN 1148’s Phase 2 study, LPCN 1154 clinical work and personnel costs.
- At June 30, cash and cash equivalents were $5.01 million and marketable securities were $20.78 million, totaling $25.79 million. Current assets were $27.08 million against current liabilities of $1.83 million. Total liabilities were $1.93 million; the SVB loan was repaid in 2022, leaving no reported debt at quarter-end.
- For the first half, operating cash use was $7.24 million; investing activities provided $9.12 million, primarily from net maturities of marketable securities; financing activities used $11,000. Cash and cash equivalents increased $1.87 million to $5.01 million. Investment maturities are not operating cash generation.
Changes, outlook and material developments
- Compared with Q2 2022, Q2 2023 revenue fell by $500,000 and net loss widened by about $917,000. R&D declined, but G&A increased, including costs associated with the reverse split, business development and franchise taxes. Higher interest and investment income partly offset operating costs; the prior-year period also included larger warrant and litigation-settlement gains.
- Management said existing capital resources and interest should fund its projected operating requirements through at least August 10, 2024, including ongoing LPCN 1148 and LPCN 1154 studies and regulatory compliance. It also said additional capital will be needed at some point; failure to obtain it could put the company’s ability to continue as a going concern at risk. Additional studies or changes to the operating plan could accelerate cash use.
- In July 2023, after quarter-end, Lipocine reported that LPCN 1148’s Phase 2 study met its primary endpoint, with reported improvements in certain clinical outcomes and tolerability similar to placebo. These are company-reported topline results, not a regulatory approval.
- For LPCN 1154, the company reported positive topline pilot PK-bridge results in May and expected to dose the first patient in a confirmatory pivotal PK study in Q4 2023. On August 4, 2023, after quarter-end, the FDA approved oral Zurzuvae for postpartum depression; its manufacturers expected a Q4 launch, subject to controlled-substance scheduling.
- The company completed a 1-for-17 reverse stock split effective May 11, 2023, to address Nasdaq’s minimum-bid-price requirement. It had 5,234,830 common shares outstanding at June 30 and 5,315,830 at August 8.
- The company’s ATM agreement had approximately $41.2 million nominally available, but Form S-3 restrictions limited the currently registered offering amount to $15.7 million. No ATM shares were sold in the reported periods. Equity issuance could dilute shareholders.
- The Antares agreement provides potential $5 million payments on each of January 1, 2025 and 2026, subject to conditions, potential sales milestones up to $160 million, and tiered U.S. royalties. Payments depend on contractual conditions and commercial performance.
Risks, contingencies and other items
- Lipocine expects continued operating losses and significant development costs. Clinical, regulatory, manufacturing and partnering outcomes are uncertain, and management cannot reliably estimate the time or cost to complete development of its candidates.
- Most non-core pipeline candidates are being pursued for partnership; no assurance is given that partners will be secured on favorable terms or at all. Further development may require additional financing, partnerships or reduced activity.
- The company reported $104,000 of warrant liability, measured using Level 3 assumptions and subject to changes in share price and other valuation inputs. It recorded non-cash warrant-liability gains of $27,000 for Q2 and $126,000 for the first half.
- A shareholder securities class action was dismissed with prejudice on April 14, 2023. Management stated that it did not believe other legal matters would materially adversely affect financial condition, liquidity or results.
- Management concluded disclosure controls were effective as of June 30, 2023; it reported no material change in internal control over financial reporting during the quarter. No off-balance-sheet arrangements were reported.
Investor verification points
- Confirm the LPCN 1148 topline findings against full study data and assess next steps, regulatory feedback and required funding.
- Track whether LPCN 1154’s pivotal PK study begins on schedule, its results and the competitive impact of Zurzuvae.
- Reconcile the expected Antares-related third-quarter receipt: the notes cite approximately $579,000 for the contract asset, while MD&A cites an anticipated $772,000 payment.
- Monitor cash burn, financing plans, ATM capacity under Form S-3 limits, and any resulting dilution or changes to the stated runway.
- Verify TLANDO sales and royalty trends, and whether Antares payment conditions and milestones are met.